Robert Stratta to Antibodies, Monoclonal
This is a "connection" page, showing publications Robert Stratta has written about Antibodies, Monoclonal.
Connection Strength
3.395
-
Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation. 2009 Sep 27; 88(6):810-9.
Score: 0.297
-
Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, Jarrett A, Adams P, Stratta R. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008 Jan-Feb; 22(1):41-9.
Score: 0.264
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 2005 Oct; 37(8):3527-30.
Score: 0.225
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc. 2005 Oct; 37(8):3531-4.
Score: 0.225
-
Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transplant Proc. 2005 Mar; 37(2):1294-6.
Score: 0.216
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. Transplant Proc. 2004 May; 36(4):1080-1.
Score: 0.204
-
Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant. 2004; 18 Suppl 12:61-6.
Score: 0.200
-
Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation. 2003 Apr 27; 75(8):1260-6.
Score: 0.190
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transplant Proc. 2002 Aug; 34(5):1903-5.
Score: 0.181
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant. 2002 Feb; 16(1):60-8.
Score: 0.175
-
Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation. 2001 Nov 27; 72(10):1637-43.
Score: 0.173
-
Stratta RJ, Alloway RR, Lo A, Hodge E. A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis. Transplant Proc. 2001 Feb-Mar; 33(1-2):1692-3.
Score: 0.163
-
Stratta RJ. Benefits and risks of early antilymphocyte rescue in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 1998 Mar; 30(2):525.
Score: 0.133
-
Stratta R, Shaefer M, Bradshaw K, Wood R, Langnas A, Zetterman R, Donovan J, Sorrell M, Markin R, Shaw BW. Experience with OKT3 after orthotopic liver transplantation. Transplant Proc. 1991 Jun; 23(3):1970.
Score: 0.083
-
Stratta RJ, Sollinger HW, D'Alessandro AM, Pirsch JD, Kalayoglu M, Belzer FO. OKT3 rescue therapy in pancreas-allograft rejection. Diabetes. 1989 Jan; 38 Suppl 1:74-8.
Score: 0.071
-
Stratta RJ, D'Alessandro AM, Hoffmann RM, Sollinger HW, Kalayoglu M, Lorentzen DF, Pirsch JD, Belzer FO. Cadaveric renal transplantation in the cyclosporine and OKT3 eras. Surgery. 1988 Oct; 104(4):606-15.
Score: 0.069
-
Sollinger HW, Stratta RJ. Experience with OKT3 in vascularized pancreas transplantation. Am J Kidney Dis. 1988 Feb; 11(2):145-8.
Score: 0.066
-
Rogers J, Stratta RJ, Lo A, Alloway RR. Impact of the metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation. Transplant Proc. 2005 Oct; 37(8):3549-51.
Score: 0.056
-
Rogers J, Stratta RJ, Lo A, Alloway RR. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients. Transplant Proc. 2005 Oct; 37(8):3552-4.
Score: 0.056
-
Lo A, Stratta RJ, Alloway RR, Hodge EE. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation. Transplant Proc. 2005 Mar; 37(2):1289-90.
Score: 0.054
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proc. 2004 May; 36(4):1076-7.
Score: 0.051
-
Stratta RJ, Rohr MS, Adams PL, Sundberg AK, Hartmann EL, Armstrong G, Anderson TK, Farney AC, Roskopf JA, Hairston G, Kiger DF, Nagaraj SK, Iskandar SS, Assimos DG. Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. Clin Transpl. 2003; 229-45.
Score: 0.047
-
Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int. 2001 Dec; 14(6):396-404.
Score: 0.043
-
Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1701-3.
Score: 0.041
-
D'Alessandro AM, Pirsch JD, Stratta RJ, Sollinger HW, Kalayoglu M, Maki DG, Belzer FO. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation. 1989 Feb; 47(2):297-300.
Score: 0.018
-
Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant. 2008 Nov-Dec; 22(6):822-8.
Score: 0.017
-
Stratta RJ, Sollinger HW, Perlman SB, D'Alessandro AM, Groshek M, Kalayoglu M, Pirsch JD, Belzer FO. Early diagnosis and treatment of pancreas allograft rejection. Transpl Int. 1988 Apr; 1(1):6-12.
Score: 0.017
-
Oh CS, Sollinger HW, Stratta RJ, Kalayoglu M, Belzer FO. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin. Transplantation. 1988 Jan; 45(1):65-7.
Score: 0.016
-
Oh CS, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation. 1988 Jan; 45(1):68-73.
Score: 0.016
-
Stratta RJ, Armbrust MJ, Lorentzen DF, Hoffman RM, D'Alessandro AM, Sollinger HW, Pirsch JD, Kalayoglu M, Belzer FO. Cadaveric renal transplantation in the cyclosporine and OKT3 eras: the University of Wisconsin-Madison experience. Clin Transpl. 1987; 183-93.
Score: 0.015
-
Saito S, Stratta RJ, Grazi GL, Castaldo P, Langnas AN, Wood RP, Shaw BW. Effect of the HLA-DRw6 antigen in liver transplantation. Transplant Proc. 1991 Feb; 23(1 Pt 2):1430-1.
Score: 0.005
-
Kalayoglu M, Stratta RJ, Hoffmann RM, Sollinger HW, Belzer FO. Quadruple immunosuppressive therapy for liver transplantation. Transplant Proc. 1988 Feb; 20(1 Suppl 1):524-9.
Score: 0.004